Evidence map›Paper›PMID 39139646›Full record

ArticleFrontiers in pharmacology2024

Effects of

Cheng-Yu Zhang, Dong-Jie Yue, Di Wang, Fei-Fei Wu

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Total flavonoids fromFrontiers in medicine · 2025
    Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Cheng-Yu ZhangDepartment of Endocrinology and Metabolism, The Fifth People's Hospital of Chongqing, Chongqing, China.
Dong-Jie YueZhengzhou Second People's Hospital, Zhengzhou City, Henan Province, China.
Di WangDepartment of Endocrinology and Metabolism, Binzhou People's Hospital, Binzhou City, Shandong Province, China.
Fei-Fei WuDepartment of Endocrinology and Metabolism, Heping Hospital Affifiliated to Changzhi Medical College, Changzhi, Shanxi Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the effects of Methods: In the study conducted at Heping Hospital of Changzhi Medical College from March 2021 to December 2022, 30 cases of patients diagnosed with diabetic nephropathy were meticulously selected as study subjects. Employing a double-blind randomized table method, these patients were randomly allocated into three groups: the control group (n = 10), the Results: 1. The 2hPBG, total cholesterol and LDL levels were observed among patients with diabetic kidney disease (DKD) across all groups: the Jin Gui Ren Qi Pill group, the Conclusion: The combination of Jin Gui Ren Qi Pill with western medical treatment exhibited superior efficacy in ameliorating clinical symptoms and reducing the ACR in patients with DKD compared to western medical treatment alone. Furthermore, this combination therapy led to an increase in the abundance of Prevotella_7 within the intestinal flora of patients, suggesting a potential enhancement in carbohydrate metabolism by the intestinal microbiota. On the other hand,

Indexed as

Bifidobacterium bifidum tetragonum tabletsdiabetic kidney diseaseintestinal florJin Gui Ren Qi Pillserum total cholesterol

Identifiers

PMID39139646
PMCPMC11319841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.